Home|Journals|Articles by Year|Audio Abstracts

Original Article

J App Pharm Sci. 2023; 13(1): 232-240

An in silico study on reproposing eravacycline as an MMP inhibitor

Deepthy Varghese, Dhilna Sunny, Anna Kurian, Tom Cherian, Leyon Varghese.

Cited by 1 Articles

Considering the role of matrix metalloproteinases (MMPs) in various pathological conditions, including cancer, they are investigated as good targets in present-day drug discovery. Tetracycline antibiotics are already being repurposed for their anticancer activities. Here, we made an investigation on some tetracycline compounds, such as demeclocycline, eravacycline, lymecycline, and omadacycline by analyzing their binding affinity with two groups of MMPs, viz, collagenases and gelatinases using in silico approach. The ΔG values of the interaction of eravacycline with different MMPs range from −8.6 Kcal/mol for MMP1 to −9.7 Kcal/mol for MMP9 indicating strong binding affinity. Further molecular dynamic simulation studies revealed that the MMP9-eravacycline interactions are highly stable and durable in virtual physiological conditions. Out of the four tetracyclines analyzed, eravacycline showed a strong broad-spectrum inhibitory potential against all the collagenase and gelatinase enzymes. This antibiotic is, therefore, recommended for further in vitro and pre-clinical validation studies to promote its repurposing in clinics.

Key words: Collagenases, Eravacycline, Gelatinases, MMPs, Reproposing, Tetracyclines.

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.